-
Company Profile
![]()
Vifor Pharma Management Ltd – Company Profile
Vifor Pharma Management Ltd (CSL Vifor) formerly Galenica Ltd, focuses on discovery, development, and marketing of prescription medicines and non-prescription drugs. The company offers intravenous pharmaceuticals for iron deficiency, besides products for nephrology and cardio-renal therapies. It also provides pharmaceuticals for the treatment of respiratory tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, hemorrhoids, chronic venous insufficiency, diabetic retinopathy, lower urinary tract infections, menometrorrhagia, chronic kidney disease, and hyperkalemia. Vifor Pharma also discovers, develops, and markets polymeric medicines...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SNF-472 in Arterial Calcification
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SNF-472 in Arterial Calcification Drug Details: SNF-472 (hexasodium phytate) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sirolimus in Lymphangioleiomyomatosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sirolimus in Lymphangioleiomyomatosis Drug Details: Sirolimus is under development for the treatment of bronchiolitis obliterans...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INS-3001 in Aortic Valve Stenosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.INS-3001 in Aortic Valve StenosisDrug Details:INS-3001 is under development for the treatment of vascular calcification in...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Levothyroxine in Hypothyroidism
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levothyroxine in Hypothyroidism Drug Details: Levothyroxine (XP-8121) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Cd19 For Lymphoma in Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Cd19 For Lymphoma in Lymphoma Drug Details:Gene therapy is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vamifeport Hydrochloride in Sickle Cell Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vamifeport hydrochloride in Sickle Cell Disease Drug Details: Vamifeport (VIT-2763) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INS-3001 in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INS-3001 in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details:INS-3001 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Patiromer Sorbitex Calcium in Resistant Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Patiromer Sorbitex Calcium in Resistant HypertensionDrug Details:Patiromer sorbitex calcium (RLY5016, Veltassa) is a cross-linked polymer of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ferric Carboxymaltose in Chemotherapy Induced Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ferric Carboxymaltose in Chemotherapy Induced Anemia Drug Details: Ferric carboxymaltose (Ferinject, Injectafer, Renegy, Feryxa) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SNF-472 in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SNF-472 in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drug Details:SNF-472 (hexasodium phytate) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Batoclimab in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Batoclimab in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drug Details:Batoclimab is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Izeltabart Tapatansine in Triple-Negative Breast Cancer (TNBC)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Izeltabart tapatansine in Triple-Negative Breast Cancer (TNBC) Drug Details: Izeltabart tapatansine is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Desidustat in Chemotherapy Induced Anemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Desidustat in Chemotherapy Induced Anemia Drug Details: Desidustat (Oxemia) is an erythropoietin-stimulating agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: NLG-207 (CRLX-101) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Famitinib in Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Famitinib in Squamous Cell Carcinoma Drug Details:Famitinib (SHR-1020) is under development for the treatment of solid...
-
Company Profile
![]()
Akebia Therapeutics Inc – Company Profile
Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company that carries out the development and commercialization of novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. Its lead product candidate vagadusta is a HIF-PH inhibitor, a regulator for the production of red blood cells, RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company's product pipeline includes AKB-5169, an oral...
Add to Basket -
Product Insights
Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hyperphosphatemia in Chronic Kidney Disease Pipeline Products Market Report Overview Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate binders and diuretics. The Hyperphosphatemia in chronic kidney disease pipeline...
-
Product Insights
![]()
Net Present Value Model: Vamifeport hydrochloride
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vamifeport hydrochloride Drug Details Vamifeport (VIT-2763)...
-
Product Insights
![]()
Net Present Value Model: Injectafer
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Injectafer Drug Details Ferric carboxymaltose (Ferinject,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.